SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa
HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...
Cancer Productivity Disparities in the Asia-Pacific Region
New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...
Generative AI Diagnosis in Neurology Enhances Non-Specialist Accuracy
Generative AI diagnosis is stepping into neurology with striking results. In a new study, ChatGPT-4o reached 65.5% accuracy for the correct leading diagnosis in challenging polyneuropathy cases, statistically matching non-specialist neurologists (63%) while trailing specialists (74%). The model o...